FNY Investment Advisers’s Passage Bio PASG Stock Holding History

FNY Investment Advisers’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-19	Closed	-$10K	–	579
2020 Q2	$10K	Buy	+19	New	+$8.54K	0.01%	278

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's PASG Position: Q3 2020 in Review

FNY Investment Advisers sold out of Passage Bio (PASG) in Q3 2020, closing a stake of 19 shares — an estimated $10K sold.

FNY Investment Advisers first reported a position in PASG in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 70 funds tracked by Wall St. Rank hold PASG as of Q3 2020.

FNY Investment Advisers reported no remaining Passage Bio position as of Q3 2020 after selling out during the quarter.
FNY Investment Advisers sold 19 Passage Bio shares in Q3 2020, an estimated $10K.
FNY Investment Advisers first reported a position in Passage Bio in Q2 2020 and held it in 1 quarter.
FNY Investment Advisers's Passage Bio position peaked at $10K in Q2 2020.
70 funds tracked by Wall St. Rank held Passage Bio as of Q3 2020.

Based on FNY Investment Advisers's 13F filing for Q3 2020, filed 9 Oct 2020.